The p53-MDM2/MDMX axis - A chemotype perspective.

The protein-protein interaction (PPI) of the tumor suppressor p53 and its negative regulator MDM2 consists of the most intense studied PPI with a group of small molecular weight antagonists described and many more disclosed in patent literature. Due to the Å-level structural insight into p53 interaction with MDM2 there is a reasonable understanding of the requirements of the molecules to bind. In contrast and despite the very close homology and 3-D similarity no potent MDMX antagonist has been disclosed up to date. The current review summarizes the different disclosed chemotypes for MDM2 including a discussion of the cocrystal structures. Structures and approaches to reconstitute functional p53 from mutated p53 are presented. Finally new screening methods and recent biotech deals based on p53 are discussed.

[1]  Xin Huang,et al.  Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction. , 2009, Journal of medicinal chemistry.

[2]  Olivier Sperandio,et al.  Rationalizing the chemical space of protein-protein interaction inhibitors. , 2010, Drug discovery today.

[3]  L. Vassilev,et al.  MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.

[4]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[5]  G. Gaidano,et al.  MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild‐type CLL with a poor cytotoxic response to Nutlin‐3 , 2010, British journal of haematology.

[6]  G. Wahl,et al.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.

[7]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[8]  S. Agarwal,et al.  Design and modular parallel synthesis of a MCR derived alpha-helix mimetic protein-protein interaction inhibitor scaffold. , 2006, Bioorganic & medicinal chemistry letters.

[9]  D. Pim,et al.  Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. , 1984, The EMBO journal.

[10]  D. L. Taylor,et al.  Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2. , 2010, Assay and drug development technologies.

[11]  A. Dömling,et al.  Discovery of pyrroloimidazoles as agents stimulating neurite outgrowth , 2006 .

[12]  Jared T. Shaw,et al.  Synthesis of diverse lactam carboxamides leading to the discovery of a new transcription-factor inhibitor. , 2007, Angewandte Chemie.

[13]  Lutz Weber,et al.  Patented inhibitors of p53–Mdm2 interaction (2006 – 2008) , 2010, Expert opinion on therapeutic patents.

[14]  Tina N. Davis,et al.  A stapled p53 helix overcomes HDMX-mediated suppression of p53. , 2010, Cancer cell.

[15]  T. Clackson,et al.  A hot spot of binding energy in a hormone-receptor interface , 1995, Science.

[16]  Dajun Yang,et al.  Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition , 2008, Proceedings of the National Academy of Sciences.

[17]  A. Levine,et al.  The first 30 years of p53: growing ever more complex , 2009, Nature Reviews Cancer.

[18]  Alan R. Fersht,et al.  Awakening guardian angels: drugging the p53 pathway , 2009, Nature Reviews Cancer.

[19]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[20]  Alexander Dömling,et al.  Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists. , 2010, Angewandte Chemie.

[21]  Alexander Dömling,et al.  The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious. , 2011, Angewandte Chemie.

[22]  S. Sebti,et al.  Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction. , 2005, Angewandte Chemie.

[23]  Jared T. Shaw,et al.  Diastereoselective Synthesis of γ-Lactams by a One-Pot, Four-Component Reaction , 2007 .

[24]  T. Holak,et al.  Molecular Basis for the Inhibition of p53 by Mdmx , 2007, Cell cycle.

[25]  T. Holak,et al.  Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain , 2008, Cell cycle.

[26]  D. Lane,et al.  T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.

[27]  R. Goodnow,et al.  Exploration of liquid and supercritical fluid chromatographic chiral separation and purification of Nutlin-3--a small molecule antagonist of MDM2. , 2007, Journal of pharmaceutical and biomedical analysis.

[28]  P. Chène.  Inhibiting the p53–MDM2 interaction: an important target for cancer therapy , 2003, Nature Reviews Cancer.

[29]  Tyler A. Davis,et al.  Catalytic, Enantioselective Synthesis of Stilbene cis-Diamines: A Concise Preparation of (-)-Nutlin-3, a Potent p53/MDM2 Inhibitor. , 2011, Chemical science.

[30]  S. Grossman,et al.  Mdm2 facilitates the association of p53 with the proteasome , 2010, Proceedings of the National Academy of Sciences.

[31]  B. Vogelstein,et al.  p53 functions as a cell cycle control protein in osteosarcomas , 1990, Molecular and cellular biology.

[32]  D. Lane,et al.  Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides. , 1994, Oncogene.

[33]  Cédric Kalinski,et al.  Isoquinolin‐1‐one Inhibitors of the MDM2–p53 Interaction , 2008, ChemMedChem.

[34]  R. Dayam,et al.  Patented small molecule inhibitors of p53–MDM2 interaction , 2006, Expert opinion on therapeutic patents.

[35]  D. L. Taylor,et al.  Implementation of a 220,000-Compound HCS Campaign to Identify Disruptors of the Interaction between p53 and hDM2 and Characterization of the Confirmed Hits , 2010, Journal of biomolecular screening.

[36]  Maxwell D Cummings,et al.  Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design. , 2006, Bioorganic & medicinal chemistry letters.

[37]  Dajun Yang,et al.  MI-63: A novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53 , 2009, British Journal of Cancer.

[38]  David C Fry,et al.  NMR structure of a complex between MDM2 and a small molecule inhibitor , 2004, Journal of biomolecular NMR.

[39]  Kristian Helin,et al.  Amplification of Mdmx (or Mdm4) Directly Contributes to Tumor Formation by Inhibiting p53 Tumor Suppressor Activity , 2004, Molecular and Cellular Biology.

[40]  Tianbao Lu,et al.  Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity. , 2006, Bioorganic & medicinal chemistry letters.

[41]  M. Kaminski,et al.  Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. , 2007, Blood.

[42]  A. Fersht,et al.  Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant. , 2010, Chemistry & biology.

[43]  M. Wolter,et al.  Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. , 1999, Cancer research.

[44]  A. Levine,et al.  The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.

[45]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[46]  G. Wahl,et al.  Targeting Mdm2 and Mdmx in Cancer Therapy: Better Living through Medicinal Chemistry? , 2009, Molecular Cancer Research.

[47]  Maxwell D Cummings,et al.  1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR. , 2005, Bioorganic & medicinal chemistry letters.

[48]  A. Kimchi,et al.  Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.

[49]  D. Vaux,et al.  Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans , 2008, Cell Death and Differentiation.

[50]  P. Ouillette,et al.  Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. , 2010, Blood.

[51]  Michael A. Dyer,et al.  MDMX: from bench to bedside , 2007, Journal of Cell Science.

[52]  Maxwell D Cummings,et al.  Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. , 2005, Journal of medicinal chemistry.

[53]  Su Qiu,et al.  Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. , 2006, Journal of medicinal chemistry.

[54]  Alexander Dömling,et al.  Small molecular weight protein-protein interaction antagonists: an insurmountable challenge? , 2008, Current opinion in chemical biology.

[55]  Frank M Boeckler,et al.  Targeted rescue of a destabilized mutant of p53 by an in silico screened drug , 2008, Proceedings of the National Academy of Sciences.

[56]  A. Unterberg,et al.  Uniform MDM2 overexpression in a panel of glioblastoma multiforme cell lines with divergent EGFR and p53 expression status. , 2006, Anticancer research.

[57]  Michael A. Dyer,et al.  Inactivation of the p53 pathway in retinoblastoma , 2006, Nature.

[58]  D. Parks,et al.  Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo , 2006, Molecular Cancer Therapeutics.

[59]  Wei Wang,et al.  Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery , 2010, Cell cycle.

[60]  J. Deschamps,et al.  Structure-based design of potent non-peptide MDM2 inhibitors. , 2005, Journal of the American Chemical Society.

[61]  A. Levine,et al.  Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[62]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.